GPCR Signaling Basics for Peptide Research Laboratories

Peptides act on many receptor classes, but G protein-coupled receptors are where a large share of peptide pharmacology takes place. If you work with peptide ligands in cell-based systems, a working grasp of GPCR signaling basics determines which assay you choose, how you interpret a potency value and whether two published numbers can be compared at all. This article walks through activation, transducer coupling, regulation and the corresponding readouts, and uses a growth hormone secretagogue receptor ligand as a concrete case.

The receptor itself

GPCRs share a seven-transmembrane helical architecture with an extracellular N-terminus and an intracellular C-terminus. They remain the largest target class in drug discovery: an analysis of approved agents and clinical candidates found that a substantial fraction of marketed drugs act through this family, with many receptors still unexploited [1].

Activation is best described as a shift in a conformational equilibrium rather than a switch. Weis and Kobilka's review of the structural evidence makes the point sharply: coupling between the orthosteric (ligand-binding) site and the intracellular transducer-binding surface is loose rather than concerted, agonist binding alone does not fully stabilise an active conformation, and distinct intermediate states whose populations shift with ligand efficacy underlie the complex pharmacology observed [2].

Three consequences follow for bench work:

1. Efficacy is a property of the ligand-receptor-transducer system, not of the ligand alone. The same peptide can look like a full agonist in one readout and a partial agonist in another.
2. Receptor expression level changes apparent potency. A high-expressing recombinant line has spare receptors, which shifts EC50 values leftward relative to a native system.
3. Basal signalling is expected, not an artefact, for some receptors.

Transducers: which G protein, and what it does

Once activated, the receptor acts as a guanine nucleotide exchange factor for a heterotrimeric G protein, promoting GDP-to-GTP exchange on the alpha subunit and dissociation into G-alpha and G-beta-gamma [2]. The four families map onto standard readouts:

Family	Immediate effector	Second messenger	Typical assay
Gs	Adenylyl cyclase (up)	cyclic AMP rise	cAMP accumulation, CRE reporter
Gi/o	Adenylyl cyclase (down)	cAMP fall	Forskolin-stimulated cAMP
Gq/11	Phospholipase C beta	IP3, DAG, Ca2+	Calcium flux, IP-One
G12/13	Rho GEFs	Rho activation	SRE reporter, Rho pulldown

A Gi-coupled receptor produces a decrease in a cAMP signal, so the assay must first be driven upward with forskolin to create a window. Getting this wrong is one of the most common reasons a peptide "shows no activity".

Regulation: kinases, arrestins, internalisation

Activated receptors are phosphorylated on intracellular serines and threonines by GPCR kinases, which recruits beta-arrestin. Arrestin binding sterically blocks further G protein coupling (desensitisation) and targets the receptor for clathrin-mediated internalisation. Lefkowitz and Shenoy reviewed the evidence that arrestins also nucleate their own signalling complexes, so arrestin recruitment is a distinct output rather than merely an off-switch [3].

This is the structural basis of biased signalling, the observation that different ligands at one receptor can favour G protein or arrestin pathways to different degrees. Practically, it means a single assay does not characterise a peptide ligand, and it explains apparent disagreements between laboratories using different readouts.

Constitutive activity and inverse agonism

Some receptors signal appreciably with no ligand present. The ghrelin receptor is a well-documented example: Holst and colleagues reported that GHS-R1a displays high constitutive signalling in the phospholipase C pathway, at a level that was a substantial fraction of its maximal agonist-stimulated response, and identified a peptide analog acting as a potent inverse agonist that suppressed this basal activity [4].

For assay design this is consequential. Against a high basal signal you can measure decreases as well as increases, and a compound classified as an "antagonist" in a stimulated assay may turn out to be an inverse agonist when the baseline is examined directly.

The GHS-R1a case

The growth hormone secretagogue receptor gives a compact illustration of how a peptide receptor is characterised. Howard and colleagues cloned the receptor from pituitary and hypothalamus, identifying it through its response to synthetic secretagogues before any endogenous ligand was known [5]. Three years later Kojima and colleagues isolated that endogenous ligand from stomach: ghrelin, a 28-residue peptide carrying an unusual n-octanoyl modification on Ser3, and reported that the acyl group was required for activity in their assays [6].

GHRP-2 is one of the synthetic hexapeptide secretagogues in this family, a short sequence built around D-amino acid and unnatural residues rather than a fragment of ghrelin. Its chemistry sets up specific experimental considerations:

• GHS-R1a is Gq-coupled, so calcium flux or IP accumulation, not cAMP, is the primary readout.
• The receptor's high constitutive activity [4] means basal signal must be measured and reported; normalising away the baseline discards real information.
• The contrast with acyl-ghrelin matters for controls. Ghrelin's octanoyl group is chemically labile to esterases in serum-containing media; a short synthetic peptide with unnatural residues has a different stability profile, so the two are not interchangeable reference agonists.
• Hydrophobic, aromatic-rich hexapeptides adsorb to plasticware at low concentrations, a general problem for peptide assays covered in peptide solubility and aggregation.

From receptor to number: what a potency value means

A concentration-response curve fitted with a four-parameter logistic yields an EC50, but its reliability depends on curve coverage. Published guidelines are explicit: the relative EC50, the midpoint between fitted upper and lower plateaus, should be reported only when at least two concentrations lie beyond each bend point of the curve, and the absolute variant requires a stable, accurately estimated 100% control [7]. Extrapolated midpoints from incomplete curves are a recurring source of unreliable potency figures in the peptide literature.

Two further points to record alongside any EC50: receptor expression level and readout. Neither is a detail; both can move a value by an order of magnitude. Assay construction is covered further in designing cell-based assays with research peptides, and stock preparation in calculating peptide stock solution concentrations. Purity and identity data for catalogue peptides used in such assays are published on our lab reports page.

Key takeaways

• GPCR activation is a conformational equilibrium; efficacy depends on the ligand, receptor and transducer together.
• Match the readout to the coupling: cAMP for Gs, forskolin-stimulated cAMP for Gi, calcium or IP for Gq.
• Beta-arrestin recruitment is a separate output, not just desensitisation, and underlies biased signalling.
• GHS-R1a has documented high constitutive activity, so baseline signal is informative and inverse agonism is measurable.
• Report receptor expression, readout and curve coverage alongside any EC50, and follow published criteria for when a midpoint is reportable.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829-842. PubMed
2. Weis WI, Kobilka BK. The molecular basis of G protein-coupled receptor activation. Annu Rev Biochem. 2018;87:897-919. PubMed
3. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308(5721):512-517. PubMed
4. Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor: identification of a potent inverse agonist. Mol Endocrinol. 2003;17(11):2201-2210. PubMed
5. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PubMed
6. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PubMed
7. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat. 2011;10(2):128-134. PubMed